MCKESSON CORPORATION

Iovance Biotherapeutics reduced its workforce by 19% in Q3 2025 and targets $100 million in annual savings to extend cash runway to late 2026.

Iovance Biotherapeutics achieved $60.0 million in total product revenue for Q2 2025, representing a 93% year-over-year increase driven by strong Amtagvi adoption.

The three largest US pharmaceutical wholesalers—Cardinal Health, Cencora, and McKesson—are leveraging vertical integration to expand their influence beyond traditional drug distribution into the buy-and-bill market.

McKesson Corporation has finalized its acquisition of Core Ventures, which includes Florida Cancer Specialists & Research Institute, to expand community-based oncology care services.

Trinity Life Sciences has formed a strategic collaboration with Ontada, a McKesson business, to provide life sciences companies with real-time oncology insights for pre- and post-launch decision making.

Ontada, a McKesson business, will present over 14 abstracts at ISPOR 2025 in Montreal, including studies on biomarker testing trends, social determinants of health, and natural language processing applications in oncology.

• Stanford Health Care has expanded its partnership with Atropos Health to embed real-world evidence directly into clinical workflows and encounter notes, enhancing point-of-care decision making without disrupting physician workflow. • The integration will work alongside Stanford's ambient AI provider, DAX from Microsoft, to generate evidence that helps clinicians finalize their notes while remaining within their existing EHR environment. • This advancement builds on Stanford's multi-year collaboration with Atropos Health, which began as the "Green Button" research project at Stanford Medicine in 2011 and has evolved to support over 2,000 affiliated physicians.

• Harrow has executed a five-year strategic supply and development agreement with the current contract manufacturing organization for TRIESENCE®, ensuring stable supply of the ocular corticosteroid. • The company has begun developing an enhanced version of TRIESENCE®, with plans to submit a new drug application (NDA) to the FDA by the end of 2027. • TRIESENCE® is FDA-approved for visualization during vitrectomy and treatment of ocular inflammatory conditions unresponsive to topical corticosteroids, addressing a product previously on the FDA's Drug Shortage List.

• Remote clinical pharmacists reviewed over 5,700 oncology orders in community practices, identifying intervention opportunities in 60% of cases, demonstrating significant clinical impact. • Integration of pharmacists led to $5.9 million reduction in medication costs and $1.4 million practice margin improvement, achieving 415% return on investment over 12 months. • Pharmacist interventions focused on patient-centered care (36%), dose optimization (35%), and therapeutic interchange (30%), while saving over 800 hours of provider time.

• A redesigned clinical decision support tool has dramatically improved biomarker documentation rates, increasing from 69% to 78% in NSCLC and 34% to 61% in mCRPC cases. • The enhanced tool aligns with typical biomarker testing timelines and reduces physician "click fatigue" by streamlining the documentation process in cancer care workflows. • Researchers plan to expand this optimized approach across 30+ cancer types, aiming to improve treatment decision support while maintaining clinical efficiency.